Avoid common mistakes on your manuscript.
Correction to: Drugs Ther Perspect https://doi.org/10.1007/s40267-018-0482-6
The article ‘Afatinib in advanced NSCLC: a profile of its use’, written by Emma D. Deeks and Gillian M. Keating, was originally published Online First without open access. After Online First publication, Boehringer Ingelheim Pharmaceuticals, Inc. requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Boehringer Ingelheim Pharmaceuticals, Inc. Further details may be found http://www.medengine.com/Redeem/C10DF0600A95D8F5. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source, provide a link to the Creative Commons license and indicate if changes were made.
The original article was corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Deeks, E.D., Keating, G.M. Correction to: Afatinib in advanced NSCLC: a profile of its use. Drugs Ther Perspect 34, 196 (2018). https://doi.org/10.1007/s40267-018-0490-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-018-0490-6